News
First living tissue 3D printed in space aboard International Space Station
Using the “Organaut”, a 3D bioprinter designed for microgravity, Russia has become the first country to print living tissue in space. After a December 3rd cargo delivery to the International Space Station (ISS), cosmonaut Oleg Kononenko completed an experiment with the machine in the Russian sector of the station, successfully producing human cartilage tissue and a rodent thyroid gland. The Organaut was designed via a collaboration with the printer’s maker, 3D Bioprinting Solutions, and Russia’s national space agency, Roscosmos. The United States also has its own bioprinting mission scheduled for the first half of 2019, joining in the march to develop biological solutions for problems that space is well suited to solve.
A 3D bioprinter operates by creating one layer at a time of specified tissue or stem cell material arranged as needed to grow and form as biologically programmed to do. As summarized by Aryeh Batt, the CEO of Precise Bio, a company dedicated to 3D printed bioproducts for human eyes, “Essentially, the biology does the work, but you have to put them in the correct environment to make it happen.” In the case of Organaut, an internal robotic mechanism drips living cell fabric layers from an automatic syringe. When living tissue is bioprinted under Earth’s gravity, the artificial cells grow in a flatter structure than their natural state in the human body. In microgravity, however, they form a shape closer to their normal dimensions.
Along with demonstrating the growth advantages of microgravity, Organaut’s tissue samples will provide the ability to study the effect of radiation on the body. “We will look at how the constructs came together, and how they behaved,” confirmed Usef Hesuani, head of laboratory projects and a managing partner of 3D Bioprinting Solutions in a recent press conference. The original Organaut printer was aboard the Soyuz MS-10 spacecraft which experienced an launch failure on October 11, 2018, forcing the U.S. and Russian crew to make an emergency landing. A second one was quickly put together for the subsequent mission.
The parent company of 3D Bioprinting Solutions is INVITRO, the largest private medical company in Russia. Founded in 1995 by Aleksandr Ostrovsky, it has 8 laboratories and over 1000 medical offices in eastern Europe, but is primarily based in Skolkovo, a high technology business area in Moscow. Bioprinting Solutions made headlines in 2015 when it printed and transplanted a functioning mouse thyroid gland. The experiment performed aboard the ISS with Organaut was a modified version of their prior work.
Unlike NASA, Roscosmos does not generally partner with private companies for its research endeavors. In an effort to inspire Russian students to enter STEM fields within their country, the agency sought to spotlight the developing bioprinting industry by using the Organaut. The successful partnership with 3D Bioprinting Solutions has now motivated the agency to continue partnering with private companies in the future. The company itself also sees advantages to collaborations of its own with other Skolkova-area manufacturers. “We have companies that are making satellite platforms…it is possible to conduct a similar experiment amid microgravity on small spacecraft [like satellites]…smaller and cheaper,” noted Ivan Kosenkov, 3D Bioprinting Solutions’ project manager.
Organaut’s printed tissues were returned to Earth with the Soyuz MS-09 spacecraft on December 20th, and the results of the experiment are expected to be published at the end of January 2019. In February, NASA plans to send a bioprinter capable of producing beating heart tissue to the ISS. Named the 3D BioFabrication Facility (BFF), the machine was developed through a partnership with two companies well-established in 3D printing and on-orbit hardware, nScrypt and Techshot. Since the thickness of heart tissue is difficult to build under gravity without structural assistance that could impede functionality, the companies developed the BFF with the hypothesis that microgravity would overcome this limitation. Thus far, the concept has been proven during parabolic flight tests, i.e., aboard the “Vomit Comet” airplane that performs multiple parabolic maneuvers in an airliner to create 20-30 seconds of weightlessness each.
Tesla CEO Elon Musk posted a photo of himself standing with the Optimus production team inside Tesla’s Fremont factory, arms crossed amid workers in hard hats and safety vests. The image captures a pivotal industrial shift: the same facility space once dedicated to building Tesla’s flagship Model S sedan and Model X SUV is now home to the company’s humanoid robot manufacturing line.
Walking the Optimus production line in Fremont pic.twitter.com/ABS0tuRibW
— Elon Musk (@elonmusk) July 1, 2026
Tesla’s Fremont Factory, acquired in 2010 from the former NUMMI joint venture between Toyota and GM, has been the company’s original U.S. manufacturing hub since Model S production began in 2012.
The Model X followed soon thereafter. These premium vehicles offered lower annual volumes, recently around 30,000 combined, compared to the high-volume Model 3 and Model Y lines that continue around the site. Over their combined run, the S and X accounted for roughly 610,000 units.
In late January 2026, during Tesla’s Q4 2025 earnings call, Elon Musk announced the end of Model S and Model X production in Q2 2026. The final vehicles rolled off the line in early May. Rather than retooling for another vehicle, Tesla chose to convert the dedicated S/X assembly area into a dedicated Optimus Gen 3 production line.
Model 3 and Y manufacturing remains unaffected. Tesla’s official Fremont Factory page now lists Optimus alongside the 3 and Y as core products.
The conversion was executed with remarkable speed. After production stopped, crews dismantled the existing vehicle line and installed entirely new modular equipment—including lines sourced from Germany and dozens of sub-lines for actuators, batteries, and other components—in roughly four months.
Musk described the timeline as “insanely fast,” noting it would be unprecedented for any other manufacturer. Initial Optimus output is expected to ramp slowly due to the robot’s roughly 10,000 unique parts and the brand-new production processes involved. The Fremont line targets an eventual capacity of 1 million Optimus units per year.
Tesla isn’t joking about building Optimus at an industrial scale: Here we go
Optimus Development Timeline
- August 19, 2021: Optimus (then called Tesla Bot) formally announced at Tesla’s first AI Day. A concept video showed a person in a suit demonstrating the vision for a general-purpose humanoid capable of dangerous, repetitive, or boring tasks using the same AI architecture as Full Self-Driving.
- 2022: Early prototypes displayed. At the second AI Day in September, semi-functional units demonstrated walking across a stage and basic arm movements
- 2023: September videos showed improved capabilities, including sorting colored blocks, precise limb awareness, and holding a Yoda pose.
- 2024-early 2025: Factory integration videos showed Optimus navigating workspaces and handling objects like battery cells.
- January 2026: Gen 3 mass-production activities began at Fremont, with reports of over 1,000 Gen 3 units already operating inside the factory for real-world learning and AI training
- April 2026: Musk confirms Optimus production on converted Fremont line would begin in late July or August 2026. The Gen 3 reveal, originally eyed for Q1, was pushed closer to production start. A second, much larger Optimus factory at Giga Texas is under construction, with volume production targeted for Summer 2027 and long-term capacity of 10 million units annually
- July 1, 2026: Musk’s on-site visit and team photo confirm the Optimus line is operational and the transition is actively progressing
Tesla positions Optimus as potentially its largest project ever, leveraging vertical integration, AI expertise, and car-like manufacturing know-how to scale humanoid robots first for its own factories and later for broader industrial and consumer use.
The Fremont conversion serves as a critical proving ground for this ambitious new chapter in Tesla’s already-rich history.
Investor's Corner
Tesla gets its latest short from Michael Burry: ‘Happy it jumped back to this level’
Tesla short seller Michael Burry, the subject of the film “The Big Short,” where he was portrayed by Steve Carell, has revealed he has opened a new bet against the stock.
In a new update to his Substack newsletter in a post titled “Trading Post June 30, 2026,” Burry revealed a new set of bets against Tesla, Caterpillar, NVIDIA, Applied Materials Inc., and the iShares Semiconductor ETF.
In regard to Tesla, Burry wrote:
“And finally I shorted Tesla at 416.22. Happy it jumped back to this level.”
This means Burry likely opened his new short position after the company’s recent rally on Wall Street, which saw Tesla shares sink in mid-May, only to recover to well over the $400 mark. Currently, shares trade at around $427.
The company saw a big Tuesday as shares climbed considerably, over 10 percent. The size of the Tesla short was not provided, nor did Burry give any information on the position’s structure, the number of shares, dollar value, or whether options were used in the short.
The Tesla and SpaceX merger everyone is talking about is quietly building
Over the years, Burry has been one of the more vocal critics of Tesla, calling its share price “media inflated,” and saying it was “ridiculously overvalued” as recently as December.
The company has largely transitioned away from being known as an automotive company and instead is much more widely regarded as an AI play, mostly due to its Full Self-Driving efforts, Optimus robot development, and data collection related to both.
This has not pulled those skeptics away from being vocal about their distaste for how Tesla is valued, but there’s no denying that the company is a global force in many things, including sustainable energy, automotive, and AI.
Wedbush Securities is initiating stock coverage on SpaceX (NASDAQ: SPCX), marking the first comments on the company since it went public several weeks ago. Wedbush and its analyst handling coverage, Dan Ives, are widely bullish on fellow Musk company Tesla (NASDAQ: TSLA).
Ives wrote his first note initiating coverage of SpaceX shares on Wednesday with a $190 price target and an ‘Outperform’ rating. The firm believes the company is well positioned off of its IPO because of its wide array of projects, including AI compute power and infrastructure, connectivity projects, and launches.
“We view SpaceX as one of the most differentiated assets within the tech market with a strong footprint across its three core markets, with Starlink driving success with connectivity,” Ives wrote, “Starship launches leading to a demand flywheel and increasing deal flow for its Colossus clusters.”
Elon Musk called it Epic: The full story of SpaceX’s Starship Flight 12
Wedbush leans heavily on Starlink, which they say is the “profitability driver given the strength of its recurring revenue base of ~12 million subscribers as of June 5th.” Ives believes Starlink is still in the “early innings” of penetrating the global telecommunications and broadband market, as it only holds less than a 1 percent share. However, this number is sure to increase over time.
It also highlights the importance of Starship, which it says is an “essential layer” of SpaceX’s overall success. SpaceX developing and displaying the ability to reuse rockets is a major cost and reliability advantage “as it reduces the necessary hardware launch costs while generating a feedback loop for future flights to improve their launch flight rate without accelerating capex spend.”
Finally, SpaceX’s recent AI/Compute projects are also very elementary, Ives writes. It is worth mentioning Wedbush said its $190 price target is derived from a valuation forecast that sees the company yielding roughly $2.48 trillion of implied enterprise value.
There are also some factors that Wedbush did not take into account with its initial coverage. The firm wrote in the note:
“We note that there is optional value coming from Starship’s accelerating scale towards sub-$200/kg unit economics, orbital data centers, and enterprise AI monetization as these factors could drive meaningful upside but these face major hurdles, so we do not take that into account with our valuation.”
SpaceX shares are down just over 2 percent today, trading at around $167 at the time of publication.
Tesla Optimus project fires up as Musk sees production line progress
Tesla gets its latest short from Michael Burry: ‘Happy it jumped back to this level’
